Effect of a serotonin precursor and uptake inhibitor in anxiety disorders; A double-blind comparison of 5-hydroxytryptophan, clomipramine and placebo

René S. Kahn, Herman G.M. Westenberg, Wim M.A. Verhoeven, Christien C. Gispen-De Wied, Wilma D.J. Kamerbeek

Research output: Contribution to journalArticlepeer-review

91 Scopus citations

Abstract

A double-blind placebo-controlled study of 5-HTP and clomipramine was carried out on 45 patients suffering from anxiety disorders (DSM-III). Clomipramine has shown to be effective in that it induced significant improvement on all rating scales as compared to placebo. 5-HTP showed a moderate reduction of the symptomatology on the 90-item symptoms checklist (SCL-90) and the State Scale of the Spielberger State-Trait Anxiety Inventory. Clomipramine and 5-HTP differed in their efficacy in that 5-HTP did not affect the associated depressive symptomatology. The results support the hypothesis that brain serotonergic pathways are involved in the pathogenesis of anxiety disorders, particularly in agoraphobia and panic disorders.

Original languageEnglish
Pages (from-to)33-45
Number of pages13
JournalInternational Clinical Psychopharmacology
Volume2
Issue number1
DOIs
StatePublished - Jan 1987
Externally publishedYes

Fingerprint

Dive into the research topics of 'Effect of a serotonin precursor and uptake inhibitor in anxiety disorders; A double-blind comparison of 5-hydroxytryptophan, clomipramine and placebo'. Together they form a unique fingerprint.

Cite this